Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event [1]

Clinical Infectious Diseases

Volumn 41, Issue 12, 2005, Pages 1820-1821

  Hainaut, Marc ^a   Peltier, Cécile Alexandra ^a   Goetghebuer, Tessa ^a   Van Der Linden, Dimitri ^a   Marissens, Denise ^b   Zissis, Georges ^b   Levy, Jack ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VIRUS RNA; ZIDOVUDINE;

ANTIBODY PRODUCTION; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFANT; LETTER; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RNA REPLICATION; SEROCONVERSION; SYMPTOMATOLOGY; VIRUS INHIBITION; VIRUS LOAD; WESTERN BLOTTING;

AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT; INFANT, NEWBORN;

EID: 28744454817     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498313     Document Type: Letter

References (7)

1. Kassuto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-73.
2. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997; 175:1051-5.
3. Jurriaans S, Sankatsing SU, Prins IM, et al. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004; 18:1607-8.
4. Connick E. Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1 infection: what is the clinical significance? Clin Infect Dis 2005; 40:874-5.
5. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336:1343-9.
6. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74:6984-91.
7. Hainaut M, Peltier CA, Gerard M, Marissens D, Zissis G, Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr 2000; 159:778-82.